SCHEMBL24673932

SCHEMBL24673932

O=C(OCc1ccccc1)c1cc2c(O)ncnc2cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 4/20 0.45
▸ GABRG2 P18507 4/20 0.45
▸ GABRB3 P28472 4/20 0.45
▸ GABRA5 P31644 4/20 0.45
▸ GABRA3 P34903 4/20 0.45
▸ GABRA2 P47869 4/20 0.45
▸ LMNA P02545 2/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ POLB P06746 2/20 0.43
▸ TSHR P16473 2/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SENP8 Q96LD8 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22732370 0.81 LMNA (0.55) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL6767245 0.78 GABRP (0.50) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL22726068 0.76 MAPT (0.47) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL2492361 0.76 POLB (0.52) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL24674535 0.75 TDP1 (0.50) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL23397122 0.74 LMNA (0.58) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL23361722 0.73 POLB (0.52) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL20305869 0.73 POLB (0.52) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL24414101 0.73 TDP1 (0.50) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL24674211 0.72 EGLN1 (0.44) LMNATDP1KMT2ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 — — US disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 — — US disclosed
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2022-07-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 GABRA1 1859/4885GABRG2 2267/4885GABRB3 1363/4885
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 GABRA1 1859/4885GABRG2 2267/4885GABRB3 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback